Payment overview · 2025
General Payments
$1,586.22
89 reported records · 17 companies
Healthcare provider profile · identity verified
Gilbert Foster, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1649262726
Verified facts
What the public records show
CMS Open Payments records show Gilbert Foster, M.D. received $1,586.22 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $326.03 | 20.6% | 26 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $314.00 | 19.8% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $222.42 | 14.0% | 13 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $159.97 | 10.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.32 | 8.3% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $83.07 | 5.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.43 | 3.0% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.08 | 2.7% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $42.20 | 2.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.80 | 2.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.55 | 2.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.94 | 2.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.16 | 1.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.15 | 1.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.58 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.59 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.93 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,586.22 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $228.99 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $179.63 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $170.47 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $163.45 | 9 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $159.97 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $142.63 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $142.63 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $131.22 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.06 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.82 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $105.82 | 8 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $101.54 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $83.07 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $79.79 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $41.43 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $7.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 87 |
| Gabapentin | Gabapentin | 276 | 75 |
| Simvastatin | Simvastatin | 261 | 60 |
| Omeprazole | Omeprazole | 250 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 65 |
| Lisinopril | Lisinopril | 227 | 61 |
| Sertraline Hcl | Sertraline Hcl | 161 | 43 |
| Clonazepam | Clonazepam | 156 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 39 |
| Losartan Potassium | Losartan Potassium | 149 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 34 |
| Ozempic | Semaglutide | 132 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 34 |
| Potassium Chloride | Potassium Chloride | 125 | 34 |
| Metformin Hcl | Metformin Hcl | 122 | 36 |
| Trazodone Hcl | Trazodone Hcl | 115 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 32 |
| Alprazolam | Alprazolam | 106 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 105 | 28 |
| Farxiga | Dapagliflozin Propanediol | 97 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 97 | 28 |
| Tramadol Hcl | Tramadol Hcl | 93 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 22 |
| Metformin Hcl Er | Metformin Hcl | 82 | 21 |
| Carvedilol | Carvedilol | 81 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 26 |
| Furosemide | Furosemide | 74 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 22 |
| Meloxicam | Meloxicam | 71 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 15 |
| Eliquis | Apixaban | 69 | 12 |
| Allopurinol | Allopurinol | 67 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 23 |
| Mirtazapine | Mirtazapine | 64 | 15 |
| Bupropion Xl | Bupropion Hcl | 62 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 24 |
| Glimepiride | Glimepiride | 59 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 32 |
| Atenolol | Atenolol | 50 | 13 |
| Finasteride | Finasteride | 49 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 44 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Naproxen | Naproxen | 39 | 13 |
| Estradiol | Estradiol | 38 | 11 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Prednisone | Prednisone | 36 | 28 |
| Celecoxib | Celecoxib | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 16 |
| Primidone | Primidone | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 14 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 11 |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 15 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Testosterone | Testosterone | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Azithromycin | Azithromycin | 13 | 13 |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,586.22 · 89 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, BEYFORTUS, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, JARDIANCE, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, PENBRAYA, PREVNAR 20, QULIPTA, Qelbree, REPATHA, REXULTI, SHINGRIX, SPRAVATO, TRUMENBA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error